1Milton DT,GJ Riely,Gomez JE,et al.Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall cell lung cancer[J].Cancer,2007,110(3):599-605.
2Amato RJ,Jac J,Giessinger S,et al.phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer[J].Cancer,2009,115(11):2438-2446.
3Motzer RJ,Escudier B,Oudard S,et al.Efficacy of everolimus in advanced renal cell carcinoma:a double blind,randomised,placebo controlled phase III trial[J].Lancet,2008,372(9637):449-456.
4Baselga J,Semiglazov V,Van Dam P,et al.Phase II randomized s tudy of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor positive breast cancer[J].J Clin Oncol,2009,27(16):2630-2637.
5Campone M,Levy V,Bourbouloux E,et al.Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours[J].Br J Cancer,2009,100(2):315-321.
6Crazzolara R,Cisterne A,Thien M,et al.Potentiating effects of RA D001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia[J].Blood,2009,113(14):3297-3306.
7Fouladi M,Laningham F,Wu J,et al.Phase I study of everolimus in pediatric patients with refractory solid tumors[J].J Clin Oncol,2007,25(30):4806-4812.
8Kirchner GI,Meier Wiedenbach I,Manns MP,et al.Clinical pharmacokinetics of everolimus[J].Clin Pharmacokinet,2004,43(2):83-95.
9Kovarik JM,Beyer D,Bizot MN,et al.Blood concentrations of ev erolimus are markedly increased by ketoconazole[J].J Clin Pharmacol,2005,45(5):514-518.
10Kovarik JM,Beyer D,Bizot MN,et al.Pharmacokinetic interaction between verapamil and everolimus in healthy subjects[J].Br J Clin Pharmacol,2005,60(4):434-437.
